Tetrahedron Letters 46 (2005) 5559–5562
Muneo Shoji,a Kaoru Shiohara,a Masato Oikawa,a Ryuichi Sakaib and Makoto Sasakia,*
aGraduate School of Life Sciences, Tohoku University, Tsutsumidori-amamiya, Aoba-ku, Sendai 981-8555, Japan
bSchool of Fisheries Science, Kitasato University, Sanriku-cho, Iwate 022-0100, Japan
Received 4 April 2005; revised 6 June 2005; accepted 8 June 2005
Abstract—Synthesis of dysiherbaine analogue 4, which corresponds to 8,9-epi-neodysiherbaine A, is described. The synthesisfeatures a concise route to the bicyclic ether skeleton through stereoselective C-glycosylation to set the C6 stereocenter and 5-exoring-closure to form the tetrahydrofuran ring. The results of preliminary biological studies of 4 are also provided. Ó 2005 Elsevier Ltd. All rights reserved.
Dysiherbaine (1), isolated from the Micronesian sponge,
Dysidea herbacea, is a novel excitatory amino acid with
potent convulsant activity.Dysiherbaine activates
namely, AMPA and kainic acid (KA) receptors, with
considerable preference over KA receptors (K
1: dysiherbaine 2: neodysiherbaine A
of 26 and 153 nM for KA and AMPA receptors, respec-tively).Moreover, it has been shown that dysiherbaine
could differentially activate one of the activation sites
within the subunit of a heteromeric GluR5/KA2 recep-tor complexThis discrete affinity of dysiherbaine has
enabled characterization of the unexpectedly complex
behavior of the heteromeric KA receptors. Neodysiher-
baine A (2isolated as a minor congener from the same
Figure 1. Structures of dysiherbaine and its analogues.
sponge, differs from dysiherbaine in the functionalgroup at the C8 position and is also a selective agonistfor non-NMDA type glutamate receptors (
tors.These studies revealed that neodysiherbaine A issimilar to dysiherbaine in its pharmacological activity
Due to these unusual pharmacological properties of
on KA receptors, albeit with slightly different binding
dysiherbaine to KA receptors and its potent epilepto-
affinities for individual receptor subunits, whereas
genic activity, dysiherbaine and its designed analogues
analogue 3, lacking the hydroxyl and N-methyl groups
are anticipated to serve as useful tools for understanding
on the tetrahydropyran ring, is a selective antagonist
the structure and functions of glutamate receptors in the
for GluR5KA receptors. These results strongly suggest
central nervous system. Thus, the total synthesis of dysi-
that the C8 and C9 functional groups are critical struc-
tural elements for specificity and selectivity for KA
receptors. In order to reveal further the detailed struc-ture–activity relationship profiles of dysiherbaine, we
Recently, Swanson and co-workers have characterized
undertook a diverted synthesis of structural analogues
the pharmacological action of neodysiherbaine A and
of dysiherbaine. In this letter, we describe a synthesis
simplified synthetic analogue 3on glutamate recep-
of dysiherbaine analogue 4, corresponding to 8,9-epi-neodysiherbaine A, for the biological evaluation.
* Corresponding author. Tel.: +81 22 717 8828; fax: +81 22 717
The synthesis started with C-glycosylation of allylsilane
6with diacetyl-L-arabinal (5).Thus, reaction of 5
0040-4039/$ - see front matter Ó 2005Elsevier Ltd. All rights reserved. doi:10.1016/j.tetlet.2005.06.093
M. Shoji et al. / Tetrahedron Letters 46 (2005) 5559–5562
Scheme 2. Reagents and conditions: (a) SO
CH2Cl2, 0 °C; (b) Ph3P@CHCO2Me, CH2Cl2, rt, 88% (two steps); (c)
DIBALH, CH2Cl2, À78 °C, 98%; (d) t-BuOOH, Ti(Oi-Pr)4, (+)-DIPT,
˚ MS, CH2Cl2, À20 °C, 95%; (e) BnNCO, i-Pr2NEt, benzene, 50 °C,
80%; (f) KOt-Bu, THF, À20 ! 0 °C, 61%; (g) NaH, CS2, MeI, THF,0 °C ! rt, 80%; (h) Bu
Scheme 1. Reagents and conditions: (a) compound 6, Yb(OTf)
(10 mol %), CH2Cl2, rt, 85%; (b) AD mix-b, MeSO2NH2, t-BuOH/H2O, 0 °C ! rt, quant.; (c) TBSOTf, Et3N, DMAP, CH2Cl2, 0 °C,
ylcarbamate with KOt-Bu afforded cyclic carbamate 14
87%; (d) K2CO3, MeOH, rt, 92%; (e) m-CPBA, CH2Cl2/pH 7
(61%). Subsequent deoxygenation was carried out
phosphate buffer, 0 °C ! rt, then SiO2, 89%; (f) Me2C(OMe)2, CSA,
according to the method of Barton and MaCombie
CH2Cl2, 0 °C, 85%; (g) H2, Pd/C, hexane, rt, 11a, 60%; 11b, 38%.
to provide 15 in 66% yield for the two steps.
depicted in Oxidation to the acid and subse-
quent esterification provided methyl ester
overall yield. Desilylation followed by oxidation with
effected regioselective dihydroxylation of the exocyclic
SO3Æpyr/DMSO afforded an aldehyde, which was
approximately 1.6:1 mixture of diastereomers, which
the three steps. Selective reduction of the enoate moiety
was carried forward without separation through the
of diester 17 was achieved by exposure to DIBALH in
subsequent transformations. The primary hydroxy
THF to yield an allylic alcohol (90%), which upon asym-
group of 8 was selectively protected as the tert-butyldi-methylsilyl (TBS) ether to give 9 in 87% yield. Afterremoval of the acetyl group (92%), treatment of the
resultant allylic alcohol with m-CPBA led exclusively
was subjected to purification by column chromato-
graphy on silica gel, epoxide ring-opening by an intra-
molecular attack of the tertiary alcohol occurred to
11b: R = CH2OH
generate diol 10 in 89% yield. Protection of the diol as
16: R = CO2Me
the acetonide (85%) followed by removal of the benzyl
group under hydrogenolysis afforded alcohols 11a
(60%) and 11b (38%), which were readily separable by
flash column chromatoThus, the synthesis of
the bicyclic ether skeleton was realized in only seven
19: R = CO2Me
Oxidation of the major alcohol 11a with SO3Æpyr/DMSO
15: R = CH2OTBS
followed by Wittig reaction, gave enoate 12 in 88% over-all yield ). DIBALH reduction and Sharpless
Scheme 3. Reagents and conditions: (a) TEMPO, NaClO2, cat.
asymmetric epoxidation using (+)-diisopropyl tartrate
NaClO, MeCN/pH 7.0 phosphate buffer, 75%; (b) K2CO3, MeI,DMF, rt, 80%; (c) TBAF, THF, rt, 85%; (d) SO
(DIPT) delivered epoxy alcohol 13 in 93% yield for the
two steps. Stereoselective introduction of the amino
2Cl2, 0 °C; (e) Ph3P@CHCO2Me, CH2Cl2, rt, 60% (two steps); (f)
DIBALH, THF, À78 °C, 90%; (g) t-BuOOH, Ti(i-PrO)4, (+)-DIPT,
group at the C2 position was carried out following the
˚ MS, À20 °C, 83%; (h) BnNCO, i-Pr2NEt, benzene, 50 °C,
procedure of Kishi and co-workersThus, treatment
95%; (i) KOt-Bu, THF, À20 °C, 78%; (j) NaH, CS2, MeI, THF,
of 13 with benzyl isocyanate (i-Pr2NEt, benzene,
0 °C ! rt, 80%; (k) Bu3SnH, AIBN, toluene, 110 °C, 75%; (l) LiBH4,
50 °C, 80%) followed by reaction of the resultant benz-
THF, 0 ! 60 °C, 74%; (m) TBSOTf, 2,6-lutidine, CH2Cl2, 0 °C, 87%.
M. Shoji et al. / Tetrahedron Letters 46 (2005) 5559–5562
metric epoxidation delivered epoxy alcohol 18 in 83%
the C8 and C9 hydroxy groups of 24 should lead to var-
yield. Elaboration of 18 to cyclic carbamate 19 was
readily accomplished as described above. The resultantester 19 was then converted to 15 by ester reduction
The toxicity of dysiherbaine analogue 4 was preliminar-
ily tested on mice. Intracerebral injection of 4 againstmice did not induce any behavioral effects such as vio-
Cyclic carbamate 15 was subsequently transformed to
lent scratching and head bobbing even at higher dose
diol 20 by a four-step sequence of protective group
manipulations, including reductive debenzylation withlithium tert-butylbiphenylide (LDBB),reprotection
In conclusion, we have developed a synthetic route to
as the Boc group, ethanolysis of the cyclic carbamate
dysiherbaine analogue 4, which features a concise synthe-
and desilylation with TBAF (). Oxidation of
sis of the bicyclic ether skeleton through stereoselective
20 with KMnO4 (1 M NaOH, H2O) gave a mixture of
C-glycosylation to set the C6 stereocenter and 5-exo cycli-
diacid 21 and aminal 22, which without separation was
zation for constructing the tetrahydrofuran ring. Further
further oxidized with catalytic amounts of tetra-n-prop-
neurophysiological studies of compound 4 and synthesis
ylammonium perruthenate (TPAP) and N-methyl-
of other analogues from a key intermediate 23 to probe
morpholine N-oxide (NMOand subsequently treated
the structure–activity relationship of dysiherbaine are
with excess trimethylsilyldiazomethane to deliver di-
in progress and will be reported in due course.
methyl ester 23 in 61% yield over the three steps. Finally,global deprotection by acid hydrolysis (6 M HCl, 65 °C)furnished the target compound 4 in 90% yThus,
the synthesis of analogue 4 was completed in 23 stepsand 3.4% overall yield from diacetyl-
This work was financially supported by Yamada Science
11a. In addition, selective deprotection of the acetonide
Foundation and a Grant-in-Aid for Scientific Research
on Priority Area ÔCreation of Biologically Functional
to give diol 24 in 85% yield.Further modification of
MoleculesÕ from the Ministry of Education, Science,Sports, Culture and Technology, Japan.
1. Sakai, R.; Kamiya, H.; Murata, M.; Shimamoto, K. J.
Am. Chem. Soc. 1997, 119, 4112–4116.
2. Sakai, R.; Swanson, G. T.; Shimamoto, K.; Contractor,
A.; Ghetti, A.; Tamura-Horikawa, Y.; Oiwa, C.; Kamiya,
H. J. Pharm. Exp. Ther. 2001, 296, 655–663.
3. Swanson, G. T.; Green, T.; Sakai, R.; Contractor, A.;
Che, W.; Kamiya, H.; Heinemann, S. F. Neuron 2002, 34,589–598.
4. Sakai, R.; Koike, T.; Sasaki, M.; Shimamoto, K.; Oiwa,
C.; Yano, A.; Suzuki, K.; Tachibana, K.; Kamiya, H. Org.
5. (a) Snider, B. B.; Hawryluk, N. A. Org. Lett. 2000, 2, 635–
638; (b) Sasaki, M.; Koike, T.; Sakai, R.; Tachibana, K.
Tetrahedron Lett. 2000, 41, 3923–3926; (c) Masaki, H.;
Maeyama, J.; Kamada, K.; Esumi, T.; Iwabuchi, Y.;Hatakeyama, S. J. Am. Chem. Soc. 2000, 122, 5216–5217;(d) Phillips, D.; Chamberlin, A. R. J. Org. Chem. 2002, 67,
6. (a) For synthetic studies on dysiherbaine, see: Naito, T.;
Nair, J. S.; Nishiki, A.; Yamashita, K.; Kiguchi, T.
Heterocycles 2000, 53, 2611–2615; (b) Huang, J.-M.; Xu,
K.-C.; Loh, T.-P. Synthesis 2003, 755–764; (c) Miyata, O.;
Iba, R.; Hashimoto, J.; Naito, T. Org. Biomol. Chem. 2003, 1, 772–774; (d) Kang, S. H.; Lee, Y. M. Synlett 2003,
7. Sasaki, M.; Maruyama, T.; Sakai, R.; Tachibana, K.
Tetrahedron Lett. 1999, 40, 3195–3198.
8. Sanders, J. M.; Ito, K.; Settimo, L.; Pentika¨inen, O. T.;
Shoji, M.; Sasaki, M.; Johnson, M. S.; Sakai, R.;
Swanson, G. T. J. Pharm. Exp. Ther. 2005, in press.
Scheme 4. Reagents and conditions: (a) LDBB, THF, À78 °C, 76%;
9. Konosu, T.; Furukawa, Y.; Hata, T.; Oida, S. Chem.
(b) Boc2O, Et3N, DMAP, CH2Cl2, 85%; (c) Cs2CO3, EtOH, rt, 95%;
˚ MS, rt, 94%; (e) KMnO4, aq NaOH, rt; (f)
10. Diacetyl-L-arabinal (5) is readily available in two steps
˚ MS, CH2Cl2, rt; (g) TMSCHN2, MeOH, rt, 61%
from L-arabinose Hullomer, F. L. In Methods in Carbo-
(three steps); (h) 6 M HCl, 65 °C, 90%; (i) DDQ, CH3CN/H2O, 50 °C,
hydrate Chemistry; Academic Press: New York, 1962; Vol.
M. Shoji et al. / Tetrahedron Letters 46 (2005) 5559–5562
11. Takhi, M.; Rahman, A. A.-H. A.; Schmidt, R. R.
16. (a) Freeman, P. K.; Hutchinson, L. L. J. Org. Chem. 1980,
Tetrahedron Lett. 2001, 42, 4053–4056.
45, 1924–1930; (b) Ireland, R. E.; Smith, M. G. J. Am.
12. The stereochemistry at C4 position of each compound was
determined by NOE experiments of the corresponding
17. Ley, S. V.; Norman, J.; Griffith, W. P.; Marsden, S. P.
18. Selected data for compound 4: ½a25 À40.0 (c 0.05, H
1H NMR (600 MHz, D2O) d 2.00 (dd, J = 15.6, 10.6 Hz,
1H, 3-H), 2.09 (dd, J = 14.1, 3.8 Hz, 1H, 5-H), 2.53 (dd,
J = 15.6, 2.3 Hz, 1H, 3-H); 2.54 (d, J = 14.1 Hz, 1H, 5-H),3.39 (dd, J = 10.6, 10.6 Hz, 1H, 10-H), 3.47 (dd, J = 10.6,
5.0 Hz, 1H, 10-H), 3.61 (dd, J = 10.6, 2.3 Hz, 1H, 2-H),
3.93 (ddd, J = 10.6, 5.0, 3.2 Hz, 1H, 9-H), 4.05 (m, 1H, 7-
H), 4.09 (m, 1H, 8-H), 4.13 (m, 1H, 6-H); 13C NMR(125MHz, D
13. Minami, N.; Ko, S. S.; Kishi, Y. J. Am. Chem. Soc.
2O) d 178.57, 174.12, 86.89, 83.97, 74.24,
67.42, 65.11, 64.43, 53.79, 44.31, 39.70; HRMS (FAB)
14. Barton, D. H. R.; MaCombie, S. W. J. Chem. Soc., Perkin
19. Tian, H.; She, X.; Yu, H.; Shu, L.; Shi, Y. J. Org. Chem.
15. Attempts to remove the benzyl group of compound 19
Psychopharmacology (2010) 211:245–257DOI 10.1007/s00213-010-1900-1Genetics of caffeine consumption and responses to caffeineAmy Yang & Abraham A. Palmer & Harriet de WitReceived: 25 March 2010 / Accepted: 25 May 2010 / Published online: 9 June 2010associated with risk of myocardial infarction in caffeineRationale Caffeine is widely consumed in foods and bev-erages and is also used